Frontlight ResearchEarly access
TerminatedNo phase
Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 3 people enrolled
- Started
- 17 Nov 2022
- Ended
- 5 Nov 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Simulated Online Adaptive Planning
- Stereotactic MRI-guided adaptive radiotherapy-SMART
- Record updated
- 10 November 2025
- Why it stopped
- \<75 % participation
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Primary lung cancer or lung metastasis from another primary
- Central tumors ≤ 2 cm from any mediastinal critical structure (proximal bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve
- Age ≥ 18 years
- Ability to understand and the willingness to sign a written informed consent
- Primary lung cancer or lung metastasis from another primary
- Central tumors ≤ 2 cm from any mediastinal critical structure (proximal bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve
- Age ≥ 18 years
- Ability to understand and the willingness to sign a written informed consent
- Determined by two thoracic radiation oncologists to require > 10-15 fraction regimens if treated with CT-based, non-adaptive radiation therapy
Who cannot take part
- Women who are pregnant. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately; Stage 2:
- Women who are pregnant. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
- Inability to tolerate MR imaging (Ie. history of claustrophobia)
- Inability to tolerate MR imaging (Ie. history of claustrophobia)
- Contraindications to MR imaging (e.g. implanted metallic prostheses, defibrillators, stimulators, pacemakers, or neurotransmitters) per institutional policy on management of patients with internal and external medical devices
- Contraindications to MR imaging (e.g. implanted metallic prostheses, defibrillators, stimulators, pacemakers, or neurotransmitters) per institutional policy on management of patients with internal and external medical devices
Other criteria
- Stage I:
Where in United States
- M D Anderson Cancer CenterHouston, United States
About the trial
What the trial wants to find out
To learn if using MRI (magnetic resonance imaging) to guide radiation therapy can help to control central lung cancer. The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study.
The 2 groups in the trial
- Stage I-(Simulated Online Adaptive Planning)Treatment being tested
Participants will receive treatment with the conventional CT-based radiation therapy and receive additional MRI scans.
Treatment: Simulated Online Adaptive Planning
- Stage II (Stereotactic MRI-guided adaptive radiotherapy-SMART)Treatment being tested
Participants will receive treatment with the investigational MRI-guided radiation therapy.
Treatment: Stereotactic MRI-guided adaptive radiotherapy-SMART
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 November 2025